Anvisa Approves Clinical Trial Modifications for 14 Investigational Drugs, Including Keytruda and Novel Oncology Agents
核心洞察
Brazil's Anvisa authorized amendments and new clinical trial dossiers for 14 investigational drugs via Resolution-RE No. 2,602, published July 1, 2026.
Approved changes include protocol amendments for pembrolizumab (Merck), volrustomig (AstraZeneca), and sacituzumab govitecan (Gilead), alongside new trial dossiers for trontinemab (Roche) and nerandomilast (Boehringer Ingelheim).
The regulatory actions span oncology, infectious disease, inflammatory conditions, and reformulations of established drugs such as ibuprofen.
The Brazilian Health Regulatory Agency (Anvisa) has greenlit a sweeping set of clinical trial modifications and new development dossiers covering 14 investigational medicines, according to Resolution-RE No. 2,602 published in the Official Gazette (Diário Oficial da União) on July 1, 2026. The decision, issued through the agency's Coordination of Clinical Research in Medicines and Biological Products, allows pharmaceutical companies to advance critical stages of human research across oncology, infectious diseases, inflammatory conditions, and reformulations of established therapies.
The approved petitions encompass substantial amendments to clinical protocols, modifications to investigational products, and technical approvals for both Specific Clinical Trial Dossiers (DEEC) and Clinical Drug Development Dossiers (DDCM). These regulatory milestones do not signal market availability but confirm that the proposed changes meet Anvisa's rigorous technical standards for participant safety and data integrity.
Oncology and Immunotherapy Advances
Several high-profile oncology programs received key approvals. Merck Sharp & Dohme secured authorization for a significant protocol amendment involving pembrolizumab, the anti-PD-1 monoclonal antibody widely used across multiple tumor types. AstraZeneca obtained approval for a substantial protocol change to its volrustomig clinical study, while Gilead Sciences received clearance for a clinical plan amendment concerning sacituzumab govitecan, an antibody-drug conjugate targeting Trop-2.
Roche gained technical approval for a clinical trial dossier for trontinemab, and Medpace received authorization for important study plan modifications involving three agents: BT8009, BCY8245, and zelenectide pevedotin. IQVIA's Debio 4326 also received a technical modification approval for the product under investigation.
Infectious Disease and Inflammatory Pipeline
Boehringer Ingelheim obtained two separate approvals: an amendment allowing continuation of experimental testing for BI 1291583 and technical permission for a specific trial dossier for nerandomilast. PSI CRO Farma secured protocol and product modifications for fosmanogepix, an investigational antifungal agent, as well as a substantial protocol amendment for pacritinib.
Eli Lilly's LY3819469 and Resolution Latin America's PRAX-628 each received authorization for technical modifications to their respective investigational products. AstraZeneca additionally gained approval for clinical development documents related to AZD5004 (elecoglipron).
Established Drug Reformulation
Beyond novel agents, Cosmed Indústria de Cosméticos e Medicamentos S.A. received approval for new research processes involving ibuprofen, a widely used synthetic nonsteroidal anti-inflammatory drug. The authorization focuses on clinical development of new formulations or dosages, reflecting ongoing industry interest in optimizing established therapeutic options.
Regulatory Framework and Next Steps
All authorized companies must adhere to standards established by Anvisa's Collegiate Board. Clinical research in Brazil proceeds through defined phases, and any mid-course modification—whether to dosing, manufacturing, or study design—requires explicit regulatory authorization to prevent unnecessary risk to trial volunteers.
With the resolution's immediate effect, pharmaceutical companies and contract research organizations may implement approved changes without delay. Should clinical trials yield positive results, data will be compiled into final sanitary registration applications. Only upon that final registration can products be sold in Brazilian pharmacies or deployed in hospital networks.
The public nature of this regulatory tracking aligns with transparency requirements of the health surveillance sector, and further updates are expected as these programs advance toward potential commercialization.